Slide 1: CytoSorbents Q1 2026 Earnings Conference Call
CytoSorbents Corporation Nasdaq: CTSO Q1 2026 Earnings Conference Call May 13, 2026
Slide 2: Conference Call Participants
Conference Call Participants Phillip Chan, MD, PhD Peter J. Mariani, CPA Efthymios Deliargyris, MD Chief Executive Officer Chief Financial Officer Chief Medical Officer 2
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation include forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our
Slide 4: Regulatory Disclaimer
Regulatory Disclaimer CytoSorb • CE Marked in Europe for the following APPROVED Indications for Use: • Cytokine Removal • Bilirubin and Myoglobin Removal • Ticagrelor and Rivaroxaban removal during cardiothoracic surgery • CytoSorb is NOT yet cleared/approved by the FDA or Health Canada • CytoSorb r
Slide 5: Operational Update
Operational Update Dr. Phillip Chan, MD, PhD Chief Executive Officer 5
Slide 6: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology CytoSorb • Treatment of l
Slide 7: Core Business Performance Summary
Core Business Performance Summary • Q1 2026 Revenue was $8.9M, up 2% from $8.7M in Q1 2025 • Direct Sales outside Germany: $2.1M vs $1.9M last year (+13% growth) • Direct Germany sales: $2.6M vs $2.8M a year ago (-7% growth) • Excellent productivity gain with a smaller, more focused team • Reflects
Slide 8: Continue to Enable Core Messaging
Continue to Enable Core Messaging Cytokine storm/ Sepsis, Septic Shock, Liver Pancreatitis Cytokine release Other Shock failure syndrome Burn Post-surgical Infectious diseases Injury Right complications Neuroinflammation (flu, COVID-19, other) Patient Organ transplant Acute Respiratory Drug overdose
Slide 9: Cost-Effectiveness of CytoSorb in Sepsis
Cost-Effectiveness of CytoSorb in Sepsis • Retrospective, observational study in 246 septic shock patients (104 standard of care (SOC) vs 142 SOC + CytoSorb) • Despite significantly higher initial disease severity at baseline, CytoSorb-treated patients demonstrated significantly: • Shorter ICU lengt
Slide 10: Clinical and Regulatory Update
Clinical and Regulatory Update Dr. Efthymios “Makis” Deliargyris, MD, FACC, FESC, FSCAI Chief Medical Officer 10
Slide 11: Blood Thinners and Cardiac Surgery
Blood Thinners and Cardiac Surgery • Tens of millions of patients globally take Direct Oral Anticoagulants (e.g, DOACs like Eliquis® and Xarelto®) and antiplatelet agents (e.g, Brilinta®) either chronically or acutely to reduce risk of heart attack, stroke, and other serious thrombotic complications
Slide 12: FDA Regulatory Update for DrugSorb-ATR and Brilinta
FDA Regulatory Update for DrugSorb-ATR and Brilinta® • FDA Appeal Decision of the original De Novo submission (August 20, 2025) • Upheld the prior denial decision, and required additional information primarily based on real-world evidence (RWE) and clinical outcomes to support the Company’s desired
Slide 13: Meanwhile, The STAR-T RCT Paper Is Now Published
Meanwhile, The STAR-T RCT Paper Is Now Published 13 DrugSorb-ATR is an investigational medical device in the U.S. and Canada and is not yet cleared or approved.
Slide 14: Potential Second Shot on Goal: DOAC Removal
Potential Second Shot on Goal: DOAC Removal • We have previously discussed our intention to pursue an expanded label for DrugSorb-ATR to include removal of DOACs following an initial marketing approval. Meanwhile, real-world evidence and publications continue to grow for this indication • Within the
Slide 15: Evidence Base for ATR Continues to Grow
Evidence Base for ATR Continues to Grow • At EuroPCR 2026 (May 19-22), the world-leading course in interventional cardiovascular medicine, next week in Paris, two key presentations will be made on antithrombotic removal: • Urgent CABG in ACS: Impact of P2Y12 Choice and Intraoperative Hemoadsorption
Slide 16: Financial Highlights
Financial Highlights Peter J. Mariani Chief Financial Officer 16
Slide 17: Q1 2026 Revenue
Q1 2026 Revenue • Revenue led by double digit growth in our direct Q1 2026 YoY Change international markets • Although German revenue is below last year, we are Revenue: $8.9m +2% encouraged by improved leadership and sales process of our smaller more focused team and plan Germany $2.6m -7% to selec
Slide 18: Q1 2026 Performance
Q1 2026 Performance 2026 2025 YoY Change Product revenue $8.9m $8.7m +2% Margins negatively impacted by lower unit Gross margin 69% 71% production levels to reduce inventory balance Reduction in R&D/clinical projects and Total operating expenses $9.2m $10.1m compensation costs Operating loss $3.0m $
Slide 19: Workforce and cost reduction program has lowered our cash burn
Workforce and cost reduction program has lowered our cash burn, and we are continuing to lower operating and production spend in 2026 • $6.4 million in cash, cash equivalents and restricted cash* (3/31/26) compared to $7.8 million (12/31/25) • $1.1 million cash burn, net of $0.3 million of restructu
Slide 20: Closing Remarks
Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer 20
Slide 21: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition We believe we have a sound plan to build and maximize shareholder value CytoSorb is an established, international core business in critical care and cardiac surgery with $37.1M in high margin product sales and an excellent “razorblade” business model with exp
Slide 22: Q&A Session
Q&A Session NASDAQ: CTSO Company Contacts: Dr. Phillip Chan - CEO pchan@cytosorbents.com Peter Mariani – CFO pmariani@cytosorbents.com 22